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ABSTRACT
Background Ischemia during kidney transplant causes chronic allograft injury and adversely affects out-
come, but the underlying mechanisms are incompletely understood. In tumors, oxygen shortage reduces
the DNA demethylating activity of the ten-11 translocation (TET) enzymes, yielding hypermethylated
genomes that promote tumor progression. We investigated whether ischemia similarly induces DNA
hypermethylation in kidney transplants and contributes to chronic injury.
Methods We proﬁled genome-wide DNA methylation in three cohorts of brain-dead donor kidney allo-
graft biopsy specimens: a longitudinal cohort with paired biopsy specimens obtained at allograft pro-
curement (preischemia; n=13), after implantation and reperfusion (postischemia; n=13), and at 3 or 12
months after transplant (n=5 each); a cross-sectional cohort with preimplantation biopsy specimens
(n=82); and a cross-sectional cohort with postreperfusion biopsy specimens (n=46).
Results Analysis of the paired preischemia and postischemia specimens revealed that methylation increased
drastically in all allografts on ischemia. Hypermethylationwas caused by loss of 5-hydroxymethylcytosine, the
product of TET activity, and it was stable 1 year after transplant. In the preimplantation cohort, CpG hyper-
methylation directly correlated with ischemia time and for some CpGs, increased 2.6% per additional hour of
ischemia.Hypermethylationpreferentially affectedand reduced theexpressionofgenes involved in suppress-
ing kidney injury and ﬁbrosis. Moreover, CpG hypermethylation in preimplantation specimens predicted
chronic injury, particularly ﬁbrosis and glomerulosclerosis, 1 year after transplant. This ﬁnding was validated
in the independent postreperfusion cohort, in which hypermethylation also predicted reduced allograft func-
tion 1 year after transplant, outperforming established clinical variables.
ConclusionsWe highlight a novel epigenetic basis for ischemia-induced chronic allograft injury with bio-
marker potential.
J Am Soc Nephrol 29: ccc–ccc, 2018. doi: https://doi.org/10.1681/ASN.2017091027
In kidney transplantation, cold ischemia time is di-
rectly proportional to delayed functioning of graf-
ted kidneys,1 overall reduced allograft function,2
and chronic allograft injury.3 Despite intensive re-
search, the pathophysiologicmechanisms underlying
ischemia-induced chronic allograft injury are still in-
sufﬁciently characterized. Experimental studies have
highlighted that cold ischemia can trigger a complex
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set of events that delay graft function and sustain renal injury.
For instance, acute ischemia can lead to chronic activation of the
host immune response to the allograft.4 Nevertheless, there are
currently no biomarkers to predict or effective treatment options
to avoid ischemia-associated allograft injury.
Recently, DNA methylation changes affecting the Ras onco-
proteininhibitorRASAL1havebeenproposed tounderliekidney
ﬁbrosis,which is a key pathologic feature contributing to chronic
allograft injury after kidney transplantation.5 DNAmethylation
is the attachment of a methyl group to cytosines located in a
CpG dinucleotide context, creating a 5-methylcytosine (5mC).
CpG dinucleotides (CpGs) tend to cluster in so-called CpG
islands, mostly within enhancers, the promoter, or ﬁrst exon
of genes, and when they are methylated, this correlates with
transcriptional silencing of the affected gene. DNA methyl-
ation represents a relatively stable but reversible epigenetic
mark.6 Its removal can be initiated by ten-11 translocation
(TET) enzymes, which convert 5mC to 5-hydroxymethylcy-
tosine (5hmC) in an oxygen-dependent manner.7 We re-
cently showed that hypoxia reduces TET activity, leading to
the accumulation of 5mC and the loss of 5hmC. In cancer
cells, this caused hypermethylation at promoters of tumor
suppressor genes.8 Speciﬁcally, we observed that, because
cancer cells are highly proliferative and subject to strong ge-
netic selection, these hypermethylation events are strongly
selected for and progressively accumulate in cancer cells.
Other medical conditions are, however, also characterized
by long-lasting oxygen shortage, but in these affected tissues,
they are far less proliferative, raising the questions of whether
DNA demethylation activity is impaired and whether this
similarly results in the hypermethylation driving disease
progression.9
However, other than the report onDNAmethylation changes
affecting RASAL1 and one other report showing a relationship
between epigenetic modiﬁcations and graft ﬁbrosis,10 DNA
methylation is only poorly characterized in the context of kidney
transplantation. Speciﬁcally, epigenome-wide studies assessing
the effects of ischemia on kidneys have never been performed,
and also, the potential link between renal ischemia, epigenetic
changes, and kidney allograft injury has never been addressed.
Therefore, because ischemia during kidney transplantation is a
major cause of chronic allograft injury and because kidneys have
the unique advantage that they are amenable to repeated biop-
sies, allowing pre- versus postischemic DNA methylation
changes to be accurately assessed within a single kidney, we
here explore whether DNA hypermethylation underlies ische-
mia-induced chronic kidney allograft injury.
METHODS
Study Design and Patients
We subjected three different cohorts of kidney transplants to
genome-wide DNA methylation proﬁling: a longitudinal
cohort of 1332 paired procurement (preischemia) and
Figure 1. Schematic overview of the study cohorts to identify ischemia-induced DNA hypermethylation during kidney transplantation
and evaluate its functional implications. 5mC, 5-methylcytosine; Tx, transplant.
Signiﬁcance Statement
Kidney transplantation is the treatment of choice for patients with
end stage renal failure. Despite improved outcome early after
transplantation, annually 3%–5% of grafts show late graft failure.
Chronic allograft injury represents a leading cause for this late
graft loss, and it has been linked to ischemia-reperfusion injury
occurring during transplantation. How ischemia-reperfusion in-
duces late allograft survival failure and how this adverse outcome
can be predicted remain largely unknown. Here, we describe how
DNA hypermethylation of renal transplants after ischemia is di-
rectly proportional to the duration of cold ischemia. We identify a
validated methylation biomarker that—measured at implantation
—predicts chronic allograft injury 1 year later. Our study, for the
ﬁrst time, highlights an epigenetic basis for ischemia-induced
chronic allograft injury.
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postreperfusion (postischemia) kidney transplant biopsies,
with an additional biopsy 3 or 12months after transplantation
in a subgroup (n=235); a second preimplantation cohort of
biopsies obtained immediately before implantation (n=82);
and a third cohort of postreperfusion biopsies (n=46; post-
reperfusion cohort). We additionally collected ten postre-
perfusion biopsies (ﬁve from living donor kidney
transplantations versus ﬁve from deceased donor transplan-
tations with long cold ischemia times) to validate DNA hy-
droxymethylation changes through liquid chromatography/
mass spectrometry (LC/MS). Machine-perfused kidneys
were excluded from all cohorts. All transplant recipients
gave written informed consent, and the study was approved
by the Ethical Review Board of the University Hospitals
Leuven (S53364). Renal biopsies were performed within
the University Hospital and centrally scored by pathologists
dedicated to renal transplant pathology following the same
standard procedures.
Epigenome-Wide Methylation Proﬁling
Genomic DNAwas extracted from all biopsies using the Allprep
DNA/RNA/miRNA Universal Kit (Qiagen, Hilden, Germany).
For genome-wide methylation analysis, DNA was bisulphite
converted using the EZ DNAMethylation Kit (Zymo Research,
Irvine, CA) and subsequently probed for DNA methylation
levels using the Illumina EPIC array (for the longitudinal and
preimplantation cohort) or the 450K array (for the postreper-
fusion cohort). TET-assisted bisulphite conversionwas used for
hydroxymethylation analysis as described.8 Quality control
consisted of removal of probes for which any sample did not
pass a 0.01 detection P value threshold, bead cutoff of 0.05, and
removal of probes on sex chromosomes. Probe annotation was
performed using Minﬁ.11
Gene Expression Proﬁling
RT-PCR was performed using OpenArray technology, a real-
time PCR-based solution for high-throughput gene expression
Table 1. Donor, transplant, and recipient characteristics of the transplants included in the different cohorts
Characteristic Longitudinal Cohort, n=13 Preimplantation Cohort, n=82 Postreperfusion Cohort, n=46
Donor
Men/women 8/5 43/39 18/28
Age, yr 43613 47615 50615
Last serum creatinine, mg/dl 0.8160.25 0.7460.25 0.7160.26a
Expanded versus standard criteria donation 1/12 25/52b 17/26c
Diabetes mellitus, N 0 (0%) 2 (2%) 2 (6%)d
Transplant
Cold ischemia time, h 10.0864.15 13.0963.96 14.5964.68
Anastomosis time, min 3265 3669 3366
Recipient
Men/women 8/5 54/28 32/14
Age, yr 55611 55612 57611
No. of HLA mismatches 361 361c 261e
Diabetes mellitus, N 5 (38%) 17 (21%) 6 (13%)
Post-transplant
CADI score at baseline 262b 262f 262g
Delayed graft function, N 3 (23%) 9 (11%) 11 (24%)
Acute rejection, N 4 (31%) 24 (29%) 12 (26%)
CADI score at 3 mo 362h 362i 262e
eGFR at 3 mo, ml/min per 1.73 m2 42613 43616c 44617e
Serum creatinine at 3 mo, mg/ml 1.7760.56 1.8260.71c 1.8260.78e
CADI score at 1 yr 462b 462j 362
eGFR at 1 yr, ml/min per 1.73 m2 45613b 52614k 50620
Serum creatinine at 1 yr, mg/ml 1.7060.45b 1.4460.40k 1.6260.60
Results are presented as mean6SD, N (%), or ratio. CADI, Chronic Allograft Damage Index.
aThirteen missing values.
bFive missing values.
cThree missing values.
dFifteen missing values.
eOne missing value.
fFourteen missing values.
gSix missing values.
hTwo missing values.
iTen missing values.
jTwenty-three missing values.
kEleven missing values.
J Am Soc Nephrol 29: ccc–ccc, 2018 Kidney Ischemia and DNA Methylation 3
www.jasn.org CLINICAL RESEARCH
analysis (Quantstudio 12K Flex Real-Time PCR system; Ther-
moﬁsher Scientiﬁc, Ghent, Belgium), for 70 transcripts that
corresponded to the protein-coding genes associated with the
66 CpG islands that were hypermethylated on ischemia at false
discovery rate (FDR),0.05 in both cohorts and the DNA
methylation modiﬁers TET1, TET2, TET3, DNMT1,
DNMT3A,DNMT3B, andDNMT3L. Five housekeeping genes
(B2M, 18S, TBP, RPL13A, and YWHAZ) were selected accord-
ing to the literature, of which 18S, TBP, and YWHAZ were
considered adequate on the basis of the gene expression
changes pre- versus postischemia. Five of 70 transcripts failed.
Statistical Analyses
Statistical analyses were performed using RStudio (version 0.99).
Raw methylation data were normalized using BMIQ and batch
corrected usingCombatwith the ChAMPpipeline.12Methylation
levels (b-values)were logarithmically transformed toM values for
all statistical tests unless stated otherwise. Results are presented as
P values and FDR values using the Benjamini and Hochberg
method. LC/MS to determine unmethylated cytosine (C), 5mC,
and 5hmC concentrations in the transplant genome was per-
formed as described.8 In the longitudinal cohort, we compared
DNAmethylation and hydroxymethylation levels pre- versus pos-
tischemia overall using Wilcoxon signed rank and paired t tests,
respectively, and subsequently at CpG site
level. In the preimplantation cohort, we ex-
amined the effect of cold ischemia time ex-
pressed as a continuous variable (in hours) on
DNA methylation for all CpGs using linear
regression adjusted for donor age and sex,
because age and sex are major determinants
of the DNAmethylome. In addition, individ-
ual CpGs were grouped according to their
associated CpG island (including shores and
shelves), and similar analyses were performed
for CpG islands: in the longitudinal cohort by
paired t tests per island and in the preim-
plantation cohort using a linear mixed
model adjusted for donor age and sex and
with transplant identiﬁer as a random ef-
fect. To evaluate locus speciﬁcally whether
changes in 5mC are mirrored by inverse
changes in 5hmC in the longitudinal co-
hort, 5mC levels for this particular analy-
sis were estimated by subtracting 5hmC
from 5mC as described previously,8 be-
cause 5mC and 5hmC are both measured
as 5mC after bisulphite conversion.
Hyper- versus hypomethylation events
were compared using binomial tests. Overlap
between cohorts was investigated by chi-
squared analysis. We annotated ischemia-
hypermethylated probes in both cohorts to
their chromatin state using chromHMM
data annotated for human fetal kidney.13
Pathway analysis was performed using DAVID, and gene on-
tology enrichment was performed using topGO in R.
Gene expression in each postischemia sample was calcu-
lated relative to the expression of the reference preischemia
sample using the ΔΔCt method with log2 transformation.
Ischemia-induced hypermethylation was correlated with
the Chronic Allograft Damage Index (CADI) score in pro-
tocol-speciﬁed allograft biopsies obtained at 3 months and 1
year after transplantation. Analyses were done unadjusted
and adjusted fordonor age (themajordeterminant of chronic
injury)14 and donor sex (which inﬂuences DNA methyl-
ation), and a separate analysis was also done for cold and
warm ischemia times. A methylation risk score (MRS) was
developed to predict chronic injury (CADI score more than
two) at 1 year after transplantation, and it was calculated as
the sum of methylation values at each CpG in 66 ischemia-
hypermethylated CpG islands weighted by marker-speciﬁc
effect size. The effect size was calculated using ridge regres-
sion (Supplemental Material). Only CpGs that were also
measured by the 450K arrays were considered to enable val-
idation in the postreperfusion cohort. The DNA MRS was
correlated to allograft function at 1 year after transplanta-
tion using the eGFR calculated by theModiﬁcation of Diet in
Renal Disease formula.15
Figure 2. DNA of kidney transplants becomes hypermethylated after ischemia. (A)
Median overall DNA methylation levels of kidney transplants before and after ische-
mia. The increase in methylation is signiﬁcant for each individual transplant pair
(P,0.001; paired Mann–Whitney U test) and also when comparing the fold increase
between median preischemic and postischemic biopsies (P,0.001). (B) Logarithmic P
values of changes in methylation at individual CpG dinucleotides (CpGs) in paired
kidney transplants comparing post- with preischemia conditions. Peaks with a gain
(red) or loss (blue) in 5-methylcytosine are highlighted at P,0.05. (C) Distribution of
the T statistics of paired tests on CpGs combined per island for all islands, showing the
skewing toward hypermethylation of kidney transplants after ischemia. (D) Difference
in DNA methylation after ischemia in and around the CpG island chr6:30852102–
30852676 located in the promoter of DDR1, showing diffuse hypermethylation of this
region.
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RESULTS
DNA Hypermethylation of Kidney Allografts after
Ischemia
To evaluate DNA methylation changes arising during cold ische-
mia, we set up a prospective clinical study to collect paired pre-
ischemic procurement and postischemic reperfusion biopsies of
13 brain-dead donor kidney transplants (Figure 1). This paired
design minimized interindividual differences, such as genetic dif-
ferences, age, and sex, which are known to profoundly inﬂuence
DNA methylation levels. The average cold is-
chemia time was 10.164.1 hours. Table 1
summarizes other donor, transplant, and re-
cipient characteristics.
DNA methylation levels were analyzed
for .850,000 CpGs using Illumina EPIC
beadchips microarrays,16 and after nor-
malization, pre- versus postischemia levels
were compared in a pairwise fashion. First,
we evaluated global DNA methylation lev-
els averaged across all probes. We observed
an increase in each transplant pair after is-
chemia (median increase: 1.3%60.9%;
P,0.001) (Figure 2A). Second, we assessed
which individual CpGs were affected by is-
chemia. We identiﬁed 91,430 differentially
methylated sites (P,0.05), most of which
showed hypermethylation in the postre-
perfusion biopsy (82,033 CpG sites; 90%;
P,0.001) (Figure 2B). Methylation levels
of these CpGs increased up to 12.1% after
ischemia. Signiﬁcantly hypermethylated
CpGs were frequently found near CpG is-
lands, particularly within CpG island
shores (20.2% versus 17.8% by random
chance; P,0.001). We, therefore, grouped
methylation of individual CpGs per CpG
island: the vast majority of CpG islands
(22,001 of 26,046; 84.5%) were hyperme-
thylated after ischemia (Figure 2C), of
which 8018 were hypermethylated after is-
chemia at P,0.05. When correcting for
multiple testing (FDR,0.05), 4156 of
26,046 islands analyzed (16.0%) were dif-
ferentially methylated, 4138 (99.6%) of
which showed hypermethylation after is-
chemia. These islands corresponded to
2388 unique genes. Interestingly, the CpG
island with the highest increase in methyl-
ation was located in the DDR1 promoter, a
gene known to be involved in apoptosis and
kidney ﬁbrosis (Figure 2D).17
Loss of DNA Hydroxymethylation on
Ischemia
Because we recently showed that low oxygen levels in tumors
inhibit DNA demethylation by reducing TETactivity8 and be-
cause in postischemic biopsies, hypermethylation was en-
riched near CpG islands, which are preferential targets of
TET enzymes,7 we measured the product of TET activity (i.e.,
5hmC). Speciﬁcally, we determined 5hmC levels genomewide
at .850,000 CpGs in six paired biopsies from our longitudi-
nal cohort. Mean 5hmC levels were lower in post- versus pre-
ischemia transplants (P,0.001 for all transplants) (Figure
3A), indicating that ischemia reduces 5hmC levels in the
Figure 3. DNA hydroxymethylation levels decrease in kidney transplants on ischemia. (A)
Overall DNA hydroxymethylation levels of transplants before (blue) and after (red) ischemia.
The decrease in hydroxymethylation is signiﬁcant for all transplants (P,0.001; paired t test).
Boxes are interquartile ranges, means are white dots, and medians are darker lines. (B) 5-
Hydroxymethylcytosine (5hmC) levels measured by liquid chromatography/mass spec-
trometry (LC/MS) show a signiﬁcant loss of 5hmC in kidney transplant biopsies from de-
ceased donation (mean of 17 hours cold ischemia time; n=5) compared with living donation
(,1 hour; n=5). (C) Changes in 5-methylcytosine (5mC) levels against changes in 5hmC
after ischemia. Colored points depict CpG dinucleotides for which the changes in 5hmC
and 5mC are signiﬁcant at P,0.05, with red used for the inverse relationship between 5mC
and 5hmC and blue used for the direct relationship.
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kidney.We then evaluated locus speciﬁcally whether changes in
5hmC are mirrored by inverse changes in 5mC. 5hmC was
indeed decreased in 351,966 of 427,724 (82.3%) CpGs with
5mC levels that increased after ischemia. When considering
CpGs at P,0.05 for both the 5hmC and the 5mC comparisons,
this relationship was even more striking: 10,493 of 10,510
(99.8%) of these CpGs with a 5mC increase showed 5hmC
loss (Figure 3C). Reductions in 5hmC were not due to changes
in TET expression, because expressions of TET1, TET2, and
TET3 were unaltered in paired pre- versus postischemic biop-
sies (P.0.05). Likewise, expression of DNAmethyltransferases
(i.e., DNMT1, DNMT3A, DNMT3B, and DNMT3L) was un-
changed.
Finally, we conﬁrmed the loss of 5hmC on ischemia using
LC/MS by comparing ﬁve postreperfusion biopsies obtained
from brain-dead donors characterized by long ischemia time
(17.964.4 hours) with ﬁve biopsies ob-
tained from living donors undergoing
minimal ischemia (326 6 minutes).
Warm ischemia (anastomosis) times
were comparable between both groups.
5hmC levels in kidney transplants from
deceased donors were, on average,
16.4%64.4% lower compared with kid-
ney transplants from living donors
(P,0.01) (Figure 3B). Together, these
ﬁndings suggest that, on ischemia, kidney
allografts become hypermethylated due to
reduced TET activity.
Dose Dependency of Ischemia-
Induced DNA Methylation Changes
Each additional hour of cold ischemia time
increases the risk of chronic allograft fail-
ure.18 Therefore, we assessed whether a
similar correlation exists between cold is-
chemia time and the extent to which ische-
mia-induced methylation changes occur.
We assembled a second independent
cross-sectional cohort of 82 postischemic
preimplantation biopsies (Figure 1, Table
1). In preimplantation biopsies, DNA
methylation levels cannot be affected by
warm ischemia or reperfusion, and there-
fore, cell composition changes cannot oc-
cur, excluding the possibility that changes
in cell type composition underlie themeth-
ylation changes.
Cold ischemia time ranged from 4.7 to
26.7 hours. Genome-wide DNA methyl-
ation levels analyzed using Illumina EPIC
beadchips were correlated with cold ische-
mia time using a linear regression adjusted
for donor sex and age. Methylation levels
correlated with cold ischemia time for
29,700 CpG sites (P,0.05), the bulk of these (21,413 CpGs;
72.1%) showing ischemia time–dependent hypermethylation
(P,0.001) (Figure 4A). In some CpGs, methylation increased
up to 2.6% with each 1-hour increase in cold ischemia time.
These CpGswere alsomore likely to be hypermethylated in the
postischemic biopsies analyzed in the longitudinal cohort
(P,0.001). Particularly, up to 2932 CpGs were hypermethy-
lated in both cohorts (P,0.05), and this mainly affected CpG
islands and shores and less frequently affected shelves and
open sea regions (Figure 4B). When classifying these 2932
CpGs on the basis of kidney chromatin state, these CpGs
were predominantly found at enhancers and gene promoters
(Figure 4C), which is in line with known TET binding sites.7
At the CpG island level, cold ischemia time signiﬁcantly
correlated with methylation levels of 189 CpG islands
(FDR,0.05 adjusted for age and sex). The vast majority of
Figure 4. Cold ischemia time correlates with the extent of ischemia-induced meth-
ylation changes. (A) Logarithmic P values obtained for individual CpG dinucleotides
(CpGs) that were correlated with the duration of cold ischemia time while adjusting for
donor age and sex. Peaks with a gain (red) or loss (blue) in 5-methylcytosine (5mC) are
highlighted at P,0.05. (B) Distribution of the CpGs hypermethylated on ischemia in
both cohorts (red) versus all probes (gray) according to their relationship with CpG
islands. (C) Observed/expected fraction of ischemia-hypermethylated CpGs over-
lapping different kidney chromatin states. (D) Logarithmic P values obtained for CpG
islands, which were correlated with the duration of cold ischemia time while adjusting
for donor age and sex. Peaks gaining (red) and losing (blue) are highlighted at false
discovery rate (FDR),0.05 and P,0.05 (light colors). (E) CpG islands hypermethylated
in the preimplantation cohort were also more likely to be hypermethylated in the
longitudinal cohort.
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these were hypermethylated (156 islands; 82.5%) (Figure 4D).
Of these 156 CpG islands, 66 (42.3%) were also hypermethy-
lated at an FDR,0.05 threshold in the longitudinal cohort
(versus 15.9% expected by random chance; P,0.001) (Figure
4E). We thus identiﬁed 66 CpG islands that were consistently
hypermethylated at a stringent multiple correction threshold
in both cohorts.
Expression Changes Due to Ischemia-Induced
Hypermethylation
Interestingly, pathway analysis on the 81 genes associated with
these 66 CpG islands revealed that genes involved in the neg-
ative regulation of the Notch and Wnt pathways, which are
strongly implicated in kidney ﬁbrosis and allograft injury,19
were enriched (Figure 5A). Other genes also played a role in
the negative regulation of apoptosis and cell death (Figure 5B).
To evaluate whether hypermethylation of these 66 CpG
islands also translates into gene expression changes within
the allograft, we assessed expression of corresponding genes
in the paired pre- versus postischemia biopsies of the longitu-
dinal cohort. Of the 65 genes for whichwe could reliably assess
expression changes, 60 (92.3%) were characterized by de-
creased expression in kidney transplants on ischemia and re-
perfusion (34 at P,0.05) (Figure 5C). These CpG islands were
mainly located in gene promoters, consis-
tent with hypermethylation suppressing
gene expression. Three genes (MSX1,
RRAD, and DLL4) were characterized by
increased expression (P,0.05), but the
corresponding hypermethylated CpG is-
lands overlapped either completely
(MSX1) or partly (RRAD and DLL4) with
gene bodies. Overall, these ﬁndings indi-
cate that methylation occurring on ische-
mia affects genes in biologically relevant
pathways and mostly decreases expression
of the associated gene.
Ischemia-Induced Hypermethylation
and Chronic Allograft Injury
Next, we assessed whether these methyl-
ation changes are stably embedded in the
kidney methylome. We, therefore, mea-
sured DNA methylation in biopsies ob-
tained several months after transplantation
(longitudinal cohort) and assessed hyper-
methylation in the 66 CpG islands. Inter-
estingly, we observed that CpGs located in
these islandswere still hypermethylated at 3
months and 1 year after transplantation
(Figure 6A).
We then investigated whether ischemia-
induced hypermethylation observed at the
time of transplantation correlates with
chronic allograft injury (calculated by the
CADI score20) (Table 1). Of the 1634 CpGs in the 66 islands,
487 (30%) CpGs were positively correlated with CADI score at
3 months (P,0.05; 332 CpGs survive multiple testing correc-
tion), and 402 (25%) CpGs were associated with CADI at 1
year (P,0.05; 135 CpGs survive multiple testing correction)
(Supplemental Figure 1). This was signiﬁcantly more than the
48 and 14 CpGs negatively correlating (P,0.05) with CADI at
3 months and 1 year, respectively. When adjusting for donor
age and sex, similar effects were observed. The bias toward a
direct correlation between hypermethylation and future in-
jury was also not detected at baseline injury, because only 43
of 75 (57%; P.0.05) CpGs correlated positively with CADI at
baseline. Also, when adjusting for cold and warm ischemia
time (Supplemental Figure 2), DNA methylation correlated
better with future injury than with injury already evident at
the time of transplantation. Similarly, adjusting for acute re-
jection when correlating methylation to future injury did not
inﬂuence these results (Supplemental Figure 3).
DNA Hypermethylation Predicts Chronic Allograft
Injury
Having shown that ischemia-induced hypermethylation of
kidney transplants correlates with chronic allograft injury,
we tested whether a methylation-based risk score at the time
Figure 5. DNA hypermethylation preferentially affects genes involved in suppression
of kidney ﬁbrosis and injury. (A) Pathway enrichment and (B) gene ontology enrich-
ment of the genes associated with the 66 CpG islands that were hypermethylated after
ischemia in both the longitudinal and preimplantation cohorts. (C) Log fold change in
the expression of hypermethylated genes after versus before ischemia in the longi-
tudinal cohort (n=2313). Each boxplot represents one transcript: red indicates that
expression is reduced after ischemia (median log fold change below one), and blue
indicates that expression in increased after ischemia (median log fold change above
one). BMP, bone morphogenetic protein. *P,0.05 by Wilcoxon test.
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of transplantation could predict chronic in-
jury 1 year after transplantation. First, we
developed an MRS reﬂecting DNAmethyl-
ation in the 66 CpG islands weighted for
their correlation with chronic injury at 1
year after transplant in the preimplantation
cohort. We deﬁned chronic injury as a
CADI.2, representing a threshold that
predicts graft survival at 1 year after trans-
plantation.20 Patients with an MRS in the
highest tertile had an increased risk (odds
ratio, 45; 95% conﬁdence interval, 8 to 499;
P,0.001) to develop chronic injury rela-
tive to patients in the lowest tertile (Figure
6, B and E). The score had an area under the
curve value of 0.919 to predict chronic in-
jury, thereby outperforming baseline clini-
cal risk factors, including donor age, donor
criteria, donor last serum creatinine, cold
ischemia time, anastomosis time, and the
number of HLAmismatches (combined area
under the curve of 0.743) (Figure 6C). The
sensitivity, speciﬁcity, and positive and nega-
tive predictive value of MRS-based ROC
curves were 90%, 90%, 95%, and 82%, re-
spectively. Because CADI combines six differ-
ent histopathologic lesions, we additionally
evaluated MRS for each lesion individually.
MRS was higher in recipients with interstitial
ﬁbrosis (P,0.001), vascular intima thicken-
ing (P=0.003) and glomerulosclerosis
(P,0.001) on the 1-year protocol-speciﬁed
Figure 6. DNA hypermethylation predicts chronic allograft injury. (A) Average DNA
methylation changes of CpG dinucleotides in the 66 CpG islands of kidney trans-
plants postischemia and postreperfusion at 3 months and 1 year after transplantation
in the longitudinal cohort compared with their preischemia procurement samples,
showing the stability of the hypermethylation. (B) Relative risk of chronic allograft
injury at 1 year after transplantation after stratifying patients into tertiles on the basis
of the methylation risk score. Odds ratios are shown for the preimplantation cohort
and replicated in the postreperfusion cohort.
(C and D) Receiver-operating characteristic
curves for the methylation risk score (red) to
predict chronic injury at 1 year after trans-
plantation compared with baseline clinical
variables (donor age, donor last serum creati-
nine, expanded versus standard criteria do-
nation, cold and warm ischemia times, and
number of HLA mismatches; blue). Curves are
shown for (C) the preimplantation cohort and
replicated in (D) the postreperfusion cohort
(P,0.01). (E and F) Chronic Allograft Damage
Index (CADI) score for each tertile on the basis
of the methylation risk score in the pre-
implantation and postreperfusion cohort. (G
and H) Allograft function by tertile of methyl-
ation risk score in the preimplantation and
postreperfusion cohort. Although eGFR levels
at 12 months were available for 71 patients,
CADI scores were available for only 59 pa-
tients. AUC, area under the curve.
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biopsies. In contrast, MRS did not differ in recipients with or
without inﬂammation (P=0.82), tubular atrophy (P=0.13), or
mesangial matrix increase (P=0.77).
Second, because chronic injury was used as an outcome
variable to assign coefﬁcients to individual CpGs in MRS
and at the same time, considered an outcome variable when
assessing the predictions of the MRS, we validated our MRS
score (on the basis of the same coefﬁcients) in an independent
cross-sectional cohort of 46 postreperfusion brain-dead donor
kidney biopsies (Table 1). We deliberately selected biopsies
taken at the postreperfusion time point to ensure robustness
and clinical validity of our observations. The highest versus
lowest tertile of patients had a ninefold increased risk to de-
velop chronic injury (CADI.2; 95% conﬁdence interval, 2 to
57; P,0.01) (Figure 6, B and F). Likewise, MRS yielded a
better area under the curve than baseline clinical risk factors
combined (area under the curve of 0.775 versus 0.694, respec-
tively) (Figure 6D). The sensitivity, speciﬁcity, and positive
and negative predictive value were 82%, 75%, 94%, and
46%, respectively.
Interestingly, patients in the highest MRS tertile also cor-
relatedwith lower eGFR levels at 1 year (ANOVA;P=0.05 in the
preimplantation cohort; P=0.01 in the postreperfusion co-
hort) (Figure 6, G and H). We additionally evaluated the cor-
relation of MRS with earlier post-transplant events. We ob-
served no correlation with delayed graft function or acute
rejection (Supplemental Material). Furthermore, although
MRS correlated with CADI at 3 months in both cohorts,
MRS failed to predict CADI.2 at 3 months in the postreper-
fusion cohort. Likewise, there was no signiﬁcant correlation
with eGFR at 3 months (Supplemental Material). Overall, this
suggests that MRS predicts changes occurring at 12 months
post-transplant but does not predict those at 3 months post-
transplant or baseline. Interestingly, when considering CADI
at the time of implantation, MRS was higher in patients who
experienced an increase in CADI at 1 year compared with
those who remained stable (P=0.02), and the highest tertile
of MRS had a signiﬁcantly increased risk of CADI progression
(P=0.03) (Supplemental Material). Patients with higher MRS
also experienced a steeper decrease in eGFR between 3 and 12
months after transplant (Supplemental Material).
DISCUSSION
In this multicohort, epigenome-wide study, we showed that cold
ischemia occurring during kidney transplantation induced DNA
hypermethylation of allografts through reduced TETDNAdeme-
thylation activity. The observed hypermethylation changes re-
mained stable for months after transplantation, downregulated
expression of associated genes, and preferentially affected genes
involved in suppression of kidney ﬁbrosis and injury. Importantly,
the resulting methylation signature predicted future chronic allo-
graft injury, and it did so with a predictive power that is superior
comparedwith a combination of clinical variables routinelymon-
itored in clinical practice.
In some CpGs, the observed DNA hypermethylation was
quite substantial, with changes mounting up to 2.6% for each
additional hour of cold ischemia time. With cold ischemia for
some transplants lastingover 24hours, the cumulative effect on
theDNAmethylome thus could become quite impactful. DNA
hypermethylation was moreover observed in different cohorts
involving biopsies obtained at different time points (e.g., pre-
implantation versus postreperfusion), thereby underscoring
the robustness of our ﬁndings. Although our data are purely
correlative by nature and therefore, fail to formally prove a
causal relationship between ischemia-induced hypermethyla-
tion and chronic allograft injury, several observations suggest
that DNA hypermethylation does causally contribute to
chronic allograft injury. For instance, we observed ischemia-
induced hypermethylation predominantly near genes involved
in the “negative” regulation of ﬁbrosis and cell death. Hyper-
methylation further silenced expression of affected genes, sug-
gesting that it triggers allograft injury. The ischemia-induced
hypermethylation was also evident up to 1 year after trans-
plantation, which is a prerequisite for DNA methylation to
induce long-term histologic changes in kidney transplants.
Moreover, when correlating methylation levels of CpG islands
measured at baseline to chronic injury, there was a strong
correlation to future injury at 12 months but not to injury
already present at baseline.
Notably, the concept of DNA hypermethylation being in-
volved in chronic allograft injury also changes our thinking on
the pathophysiology underlying ischemia-induced chronic al-
lograft injury. Hitherto, chronic allograft injury has mainly
been considered to be driven indirectly by a host immune
response to acute injury.4 Our data support a more direct
and lasting effect of ischemia on graft ﬁbrosis and suggest
that inhibitors of DNAmethylation represent promising ther-
apeutic agents to prevent chronic allograft injury. Indeed,
DNA methylation changes are generally considered to be re-
versible, and DNA methylation inhibitors are already
approved for the treatment of hematologic malignancies.21
Another possibility is to use compounds that induce TET ac-
tivity, thereby preventing TET suppression on ischemia, pro-
hibiting DNA hypermethylation of the graft, and protecting it
from future chronic injury. Although all of these therapies
might entail important side effects, there is the possibility
to speciﬁcally treat grafts during their preservation, thereby
preventing systemic side effects in the recipient. Impor-
tantly, however, epigenome-wide methylation proﬁling of
whole-kidney biopsies did not allow us to assess in which
cells methylation changes occurred. Recently developed sin-
gle-cell methylation analyses22 are needed to overcome this
limitation. Furthermore, the relevance of the methylation
changes could be assessed by determining the accessibility
of the affected genes to transcription (for instance, by chip-
ping with an RNA pol2 antibody).23
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Our ﬁndings also bear important biomarker potential. In-
deed, we reliably predicted chronic allograft injury 1 year after
transplantation by assessing methylation at the time of trans-
plantation in those CpG islands becoming consistently hyper-
methylated on ischemia. In an independent replication cohort,
the tertile of patientswith the highestMRS exhibited a ninefold
increased risk of developing allograft injury relative to patients
with the lowest risk. Currently, the risk of developing chronic
allograft injury is estimated on the basis of clinical risk factors,
such as donor age and ischemia time, but in a head to head
comparison, our MRS outperformed the combined predictive
effect of these baseline clinical variables.
Mechanistically, our ﬁndings build on previous observa-
tions that we had in solid tumors, in which reduced TET
DNA demethylation activity led to DNA hypermethylation
of gene promoters and enhancers.8 TET enzymes are Fe2+
and a-ketoglutarate–dependent dioxygenases that oxidize
5mC to 5hmC,24 which is then further oxidized to other de-
methylation intermediates and subsequently, replaced by an
unmodiﬁed cytosine, leading to DNAdemethylation.25 In line
with these ﬁndings, we observe in kidney allografts subjected
to cold ischemia that DNA hypermethylation was also en-
riched in regions known to be TET binding sites (i.e., gene
promoter and enhancer regions).7 Furthermore, each hyper-
methylation event was mirrored by an inverse change in
5hmC, indicating that DNA hypermethylation occurs through
reduced TETactivity. Although the underlying mechanisms in
transplanted kidneys thus seem to be akin to those operating
in tumors, our observations are quite surprising. Indeed, in
transplanted kidneys, oxygen levels are lower than in tumors
(0.1% versus 0.3%–0.5%), but ischemia time is much shorter
(on average, 24 hours during transplantation versus months
to even years in tumors). Furthermore, cancer cells are highly
proliferative and can select for epigenetic changes conferring a
survival beneﬁt. In contrast, kidneys are characterized by low
levels of cell proliferation, which reduce the potential for sta-
bilization of epigenetic changes through cellular selection. In-
terestingly, the functional implications of our ﬁndings may be
translated to other ﬁelds of medicine. Indeed, other than
obvious implications in other transplant settings, they may
be of relevance for other ischemic diseases, for which it would
be less straightforward to show similar mechanisms. Per-
forming paired biopsies in patients is indeed nearly impos-
sible in other ischemic diseases, such as stroke or myocardial
infarction, and also, the correlation of epigenetic changes
with ischemia time would be challenging, because the exact
onset of ischemia is almost impossible to determine in these
pathologies.
In conclusion, we here describe a novel epigenetic mecha-
nism that links ischemia at the time of kidney transplantation
with progressive chronic allograft injury after transplantation.
Because DNAmethylation is generally considered to be revers-
ible, our results can have further therapeutic applications for
the prevention of chronic allograft injury, a disease that is
currently lacking therapeutic options.
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